Treating cancer in older and oldest old patients

Current Pharmaceutical Design

Volumn 21, Issue 13, 2015, Pages 1699-1705

  Colloca, G ^a   Corsonello, A ^b   Marzetti, E ^a   Balducci, L ^c   Landi, F ^a   Extermann, M ^c   Scambia, G ^a   Cesari, M ^d,e   Carreca, I ^f   Monfardini, S ^g   Bernabei, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b INRCA   (Italy)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF PALERMO   (Italy)

^g IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Cancer; CGA; Elderly; Fatigue; Frailty; Oldest old; Sarcopenia

Indexed keywords

AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHRONIC DISEASE; ENVIRONMENTAL FACTOR; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HEREDITY; HUMAN; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SARCOPENIA; STRESS; AGE; NEOPLASMS; VERY ELDERLY;

AGE FACTORS; AGED, 80 AND OVER; HUMANS; NEOPLASMS;

EID: 84929661523     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150130122536     Document Type: Article

References (69)

1. Fried LP, Hall WJ. Editorial: Leading on behalf of an aging soci-ety. J Am Geriatr Soc 2008; 56(10): 1791-5.
2. Colloca G, Santoro M, Gambassi G. Age-related physiologicchanges and perioperative management of elderly patients. SurgOncol 2010; 19(3): 124-30.
3. Rosenthal RA, Kavic SM. Assessment and management of thegeriatric patient. Crit Care Med 2004; 32(4 Suppl): S92-105.
4. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathyof the aging human heart. Myocyte loss and reactive cellular hyper-trophy. Circ Res 1991; 68(6): 1560-8.
5. Chen CH, Ting CT, Lin SJ, et al. Which arterial and cardiac pa-rameters best predict left ventricular mass? Circulation 1998;98(5): 422-8.
6. Krumpe PE, Knudson RJ, Parsons G, Reiser K. The aging respira-tory system. Clin Geriatr Med 1985; 1(1): 143-75.
7. EDGE JR, MILLARD FJ, REID L, SIMON G. THE RADIO-GRAPHIC APPEARANCES OF THE CHEST IN PERSONS OFADVANCED AGE. Br J Radiol 1964; 37: 769-74.
8. Verbeken EK, Cauberghs M, Mertens I, Clement J, Lauweryns JM, Van de Woestijne KP. The senile lung. Comparison with normaland emphysematous lungs. 1. Structural aspects. Chest 1992;101(3): 793-9.
9. Lonergan ET., Aging and the kidney: adjusting treatment to physiologic change. Geriatrics 1988; 43(3): 27-30, 32-3.
10. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on therate of decline in renal function with age. J Am Geriatr Soc 1985;33(4): 278-85.
11. Palmer BF. Disturbances in renal autoregulation and the suscepti-bility to hypertension-induced chronic kidney disease. Am J MedSci 2004; 328(6): 330-43.
12. Esposito C, DalCanton A. Functional changes in the aging kidney. J Nephrol. 23 Suppl 1: S41-5.
13. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends inhypertension prevalence, awareness, treatment, and control in olderU.S. adults: data from the National Health and Nutrition Examina-tion Survey 1988 to 2004. J Am Geriatr Soc 2007; 55(7): 1056-65.
14. Pannarale G, Carbone R, Del Mastro G, et al. The aging kidney:structural changes. J Nephrol. 23 Suppl 1: S37-40.
15. Zeeh J. The aging liver: consequences for drug treatment in oldage. Arch Gerontol Geriatr 2001; 32(3): 255-63.
16. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of ageand gender on in vitro properties of human liver microsomalmonooxygenases. Clin Pharmacol Ther 1990; 48(4): 365-74.
17. Herd B, Wynne H, Wright P, James O, Woodhouse K. The effectof age on glucuronidation and sulphation of paracetamol by humanliver fractions. Br J Clin Pharmacol 1991; 32(6): 768-70.
18. Schmucker DL. Liver function and phase I drug metabolism in theelderly: a paradox. Drugs Aging 2001; 18(11): 837-51.
19. Schmucker DL, Sachs H. Quantifying dense bodies and lipofuscinduring aging: a morphologist’s perspective. Arch Gerontol Geriatr. 34(3): 249-61.
20. Cesari M, Leeuwenburgh C, Lauretani F, et al. Frailty syndromeand skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr 2006; 83(5): 1142-8.
21. Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Singh MAF. Longitudinal changes in body composition in older men andwomen: role of body weight change and physical activity. Am JClin Nutr 2002; 76(2): 473-81.
22. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Mor-row GR. Cancer-related fatigue: the scale of the problem. Oncolo-gist 2007; 12 Suppl 1: 4-10.
23. Luciani A, Jacobsen PB, Extermann M, et al. Fatigue and func-tional dependence in older cancer patients. Am J Clin Oncol 2008;31(5): 424-30.
24. Weis J. Cancer-related fatigue: prevalence, assessment and treat-ment strategies. Expert Rev Pharmacoecon Outcomes Res 2011;11(4): 441-6.
25. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha2b interferon and 13 cis retinoic acid in patients with metastaticmelanoma. Am J Clin Oncol 1998; 21(4): 352-4.
26. Schmidt ME, Chang-Claude J, Vrieling A, Heinz J, Flesch-Janys D, Steindorf K. Fatigue and quality of life in breast cancer survi-vors: temporal courses and long-term pattern. J Cancer Surviv 2012; 6(1): 11-9.
27. Meng H, Hale L, Friedberg F. Prevalence and predictors of fatiguein middle-aged and older adults: evidence from the health and re-tirement study. J Am Geriatr Soc 2010; 58(10): 2033-4.
28. Marzetti E, Calvani R, Bernabei R, Leeuwenburgh C. Apoptosis inskeletal myocytes: a potential target for interventions against sar-copenia and physical frailty -a mini-review. Gerontology 2012;58(2): 99-106.
29. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable?Results of a multi-centre patient survey. Cancer Fatigue Forum.Ann Oncol 2000; 11(8): 971-5.
30. Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal musclemitochondrial function with aging in humans. Proc Natl Acad SciUSA 2005; 102(15): 5618-23.
31. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunctionin the elderly: possible role in insulin resistance. Science 2003;300(5622): 1140-2.
32. Conley KE, Jubrias SA, Esselman PC. Oxidative capacity andageing in human muscle. J Physiol 2000; 526 Pt 1: 203-10.
33. Coen PM, Jubrias SA, Distefano G, et al. Skeletal Muscle Mito-chondrial Energetics Are Associated With Maximal Aerobic Ca-pacity and Walking Speed in Older Adults. J Gerontol A Biol SciMed Sci 2012.
34. Joseph A-M, Adhihetty PJ, Buford TW, et al. The impact of agingon mitochondrial function and biogenesis pathways in skeletalmuscle of sedentary high-and low-functioning elderly individuals. Aging Cell 2012; 11(5): 801-9.
35. Mastrocola R, Reffo P, Penna F, et al. Muscle wasting in diabeticand in tumor-bearing rats: role of oxidative stress. Free Radic BiolMed 2008; 44(4): 584-93.
36. Wong R, Lopaschuk G, Zhu G, et al. Skeletal muscle metabolismin the chronic fatigue syndrome. In vivo assessment by 31P nuclearmagnetic resonance spectroscopy. Chest 1992; 102(6): 1716-22.
37. Pietrangelo T, Mancinelli R, Toniolo L, et al. Transcription profileanalysis of vastus lateralis muscle from patients with chronic fa-tigue syndrome. Int J Immunopathol Pharmacol. 22(3): 795-807.
38. Fulle S, Mecocci P, Fanó G, et al. Specific oxidative alterations invastus lateralis muscle of patients with the diagnosis of chronic fa-tigue syndrome. Free Radic Biol Med 2000; 29(12): 1252-9.
39. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction,fatigue and the adverse effects of chemotherapy of metastatic dis-ease by molecular replacement therapy. Clin Exp Metastasis 2008;25(2): 161-9. doi: 10.1007/s10585-007-9129-z.
40. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults:evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56(3): M146-56.
41. World Health Organization. International classification of impair-ments, disabilities and handicaps: a manual of classification relat-ing to the consequences of disease. Revised Edition (1980) ed. Ge-neva: World Health Organization, 1993.
42. Buchner DM, Wagner EH. Preventing frail health. Clin GeriatrMed 1992; 8(1): 1-17.
43. Ferrucci L, Guralnik JM, Studenski S, Fried LP, Cutler GB, Wal-ston JD. Designing randomized, controlled trials aimed at prevent-ing or delaying functional decline and disability in frail, older per-sons: a consensus report. J Am Geriatr Soc 2004; 52(4): 625-34.
44. Walston J, McBurnie MA, Newman A, et al. Frailty and activationof the inflammation and coagulation systems with and withoutclinical comorbidities: results from the Cardiovascular HealthStudy. Arch Intern Med 2002; 162(20): 2333-41.
45. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-yearmortality in older adults: the Cardiovascular Health Study. JAMA 1998; 279(8): 585-92.
46. Judge JO, Schechtman K, Cress E. The relationship between physi-cal performance measures and independence in instrumental activi-ties of daily living. The FICSIT Group. Frailty and Injury: Coop-erative Studies of Intervention Trials. J Am Geriatr Soc 1996;44(11): 1332-41.
47. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as apredictor of subsequent disability. N Engl J Med 1995; 332(9):556-61.
48. Cesari M, Kritchevsky SB, Penninx BWHJ, et al. Prognostic valueof usual gait speed in well-functioning older people--results fromthe Health, Aging and Body Composition Study. J Am Geriatr Soc 2005; 53(10): 1675-80.
49. Studenski S, Perera S, Patel K, et al. Gait speed and survival inolder adults. JAMA 2011; 305(1): 50-8.
50. Audisio RA, Bozzetti F, Gennari R, et al. The surgical managementof elderly cancer patients; recommendations of the SIOG surgicaltask force. Eur J Cancer 2004; 40(7): 926-38.
51. Audisio RA, Pope D, Ramesh HSJ, et al. Shall we operate? Preop-erative assessment in elderly cancer patients (PACE) can help. ASIOG surgical task force prospective study. Crit Rev Oncol Hema-tol 2008; 65(2): 156-63.
52. Lichtman SM, Wildiers H, Chatelut E, et al. International Societyof Geriatric Oncology Chemotherapy Taskforce: evaluation ofchemotherapy in older patients--an analysis of the medical litera-ture. J Clin Oncol 2007; 25(14): 1832-43.
53. Balducci L, Corcoran MB. Antineoplastic chemotherapy of theolder cancer patient. Hematol Oncol Clin North Am 2000; 14(1):193-212 , x-xi.
54. Extermann M, Boler I, Reich RR, et al. Predicting the risk of che-motherapy toxicity in older patients: the Chemotherapy Risk As-sessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118(13): 3377-86.
55. Maloney KW, Kagan SH. Adherence and oral agents with olderpatients. Semin Oncol Nurs 2011; 27(2): 154-60.
56. Gonsalves W, Ganti AK. Targeted anti-cancer therapy in the eld-erly. Crit Rev Oncol Hematol 2011; 78(3): 227-42.
57. Zachariah B, Casey L, Balducci L. Radiotherapy of the oldest oldcancer patients: a study of effectiveness and toxicity. J Am GeriatrSoc 1995; 43(7): 793-5.
58. Haas ML. Utilizing geriatric skills in radiation oncology. GeriatrNurs 25(6): 355-60.
59. Wildiers H, Heeren P, Puts M, et al. International Society of Geri-atric Oncology Consensus on Geriatric Assessment in Older Pa-tients With Cancer. J Clin Oncol 2014.
60. Caillet P, Canoui-Poitrine F, Vouriot J, et al. Comprehensive geri-atric assessment in the decision-making process in elderly patientswith cancer: ELCAPA study. J Clin Oncol 2011; 29(27): 3636-42.
61. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatricassessment adds information to Eastern Cooperative OncologyGroup performance status in elderly cancer patients: an ItalianGroup for Geriatric Oncology Study. J Clin Oncol 2002; 20(2):494-502.
62. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new methodof classifying prognostic comorbidity in longitudinal studies: de-velopment and validation. J Chronic Dis 1987; 40(5): 373-83.
63. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J AmGeriatr Soc 1968; 16(5): 622-6.
64. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbineversus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18(13): 2529-36.
65. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable EldersSurvey: a tool for identifying vulnerable older people in the com-munity. J Am Geriatr Soc 2001; 49(12): 1691-9.
66. Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools formultidimensional health problems warranting a geriatric assess-ment in older cancer patients: an update on SIOG recommenda-tions. Ann Oncol 2014.
67. Mangoni AA, Jackson SHD. Age-related changes in pharmacoki-netics and pharmacodynamics: basic principles and practical appli-cations. Br J Clin Pharmacol 2004; 57(1): 6-14.
68. Bernabei R, Landi F, Onder G, Liperoti R, Gambassi G. Secondand third generation assessment instruments: the birth of standardi-zation in geriatric care. J Gerontol A Biol Sci Med Sci 2008; 63(3):308-13.
69. Balducci L. Management of cancer in the elderly. Oncology(Williston Park) 2006; 20(2): 135-43; discussion 144, 146, 151-2.